In Brief This Week: Clarity Pharmaceuticals, Regenxbio, Rocket Pharmaceuticals, Eisai, AstraZeneca
News items for the week of May 22, 2023.
AstraZeneca Sees New Lung Cancer Indication for Tagrisso, Chemo in FLAURA2 Data
Based on high-level results from the trial, the firm believes the combination could be a new first-line option for patients with advanced EGFR-mutated NSCLC.
FDA Sends Byondis Complete Response Letter Delaying Decision on HER2-Positive Breast Cancer Drug
Byondis submitted data on SYD985's activity from the Phase III TULIP trial, but the agency has requested additional information.
EU Expands Indication for AstraZeneca's C5 Protein Inhibitor Ultomiris
Ultomiris is now available in the EU for AQP4 antibody-positive neuromyelitis optica spectrum disorder, a rare autoimmune disease.
The drugmaker is hyping its recent acquisition announcement against an overall 29 percent revenue decline and 4 percent oncology sales dip during Q1 2023.